Addgene: Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD(+) Bioavailability and Inhibition of Poly-ADP-Ribose Glycohydrolase.

This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Browse
Robert Sobol
Li et al

Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD(+) Bioavailability and Inhibition of Poly-ADP-Ribose Glycohydrolase.
Li J, Koczor CA, Saville KM, Hayat F, Beiser A, McClellan S, Migaud ME, Sobol RW
Cancers (Basel). 2022 Jul 22;14(15). pii: cancers14153572. doi: 10.3390/cancers14153572. PubMed Article

Plasmids from Article

ID	Plasmid	Purpose
187654	pIRES-Puro-MGMT	Expresses hMGMT together with the puromycin resistance gene via an IRES.

Plasmids from Article

Antibodies from Article

Help Center

Deposit Plasmids

General Reagents

Viral Service

DNA Service

Plasmid Collections

	More than 20 requests
	More than 50 requests
	More than 100 requests